J. Safra Sarasin Holding AG Has $9.62 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB)

J. Safra Sarasin Holding AG lessened its holdings in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 13.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 62,873 shares of the biotechnology company's stock after selling 9,745 shares during the period. J. Safra Sarasin Holding AG's holdings in Biogen were worth $9,615,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in BIIB. Larson Financial Group LLC raised its holdings in Biogen by 640.9% in the 4th quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company's stock valued at $25,000 after acquiring an additional 141 shares in the last quarter. Lee Danner & Bass Inc. acquired a new position in Biogen in the 4th quarter valued at approximately $25,000. OFI Invest Asset Management acquired a new position in Biogen in the 4th quarter valued at approximately $32,000. SRS Capital Advisors Inc. acquired a new position in Biogen in the 4th quarter valued at approximately $33,000. Finally, Golden State Wealth Management LLC acquired a new position in Biogen in the 4th quarter valued at approximately $41,000. Institutional investors and hedge funds own 87.93% of the company's stock.

Biogen Trading Down 0.6 %

NASDAQ:BIIB traded down $0.67 on Friday, hitting $118.84. 1,538,299 shares of the stock were exchanged, compared to its average volume of 1,350,289. The stock has a market capitalization of $17.40 billion, a price-to-earnings ratio of 10.62, a P/E/G ratio of 1.51 and a beta of 0.06. Biogen Inc. has a 52 week low of $110.04 and a 52 week high of $238.00. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35. The company's 50-day moving average price is $132.47 and its 200 day moving average price is $148.86.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, beating analysts' consensus estimates of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%. On average, equities research analysts forecast that Biogen Inc. will post 15.83 earnings per share for the current year.

Insider Activity

In related news, Director Stephen A. Sherwin sold 8,760 shares of the business's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $150.02, for a total value of $1,314,175.20. Following the completion of the transaction, the director now directly owns 11,318 shares in the company, valued at approximately $1,697,926.36. The trade was a 43.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have commented on BIIB shares. Needham & Company LLC reaffirmed a "hold" rating on shares of Biogen in a report on Friday. Royal Bank of Canada increased their target price on Biogen from $221.00 to $225.00 and gave the stock an "outperform" rating in a report on Tuesday, April 22nd. Wells Fargo & Company decreased their price target on Biogen from $165.00 to $140.00 and set an "equal weight" rating on the stock in a research note on Thursday, February 13th. Argus lowered Biogen from a "buy" rating to a "hold" rating in a research note on Friday, April 4th. Finally, Bank Of America (Bofa) reduced their target price on shares of Biogen from $178.00 to $163.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 11th. Eighteen equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat.com, Biogen presently has an average rating of "Hold" and a consensus target price of $211.37.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.